Winrevair, sotatercept
Named-patient access overview. Winrevair is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Winrevair
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Winrevair
Winrevair (sotatercept) is manufactured by Merck (via Acceleron) and indicated for Pulmonary arterial hypertension. It is a Fusion protein approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Winrevair
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Winrevair for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Winrevair is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Winrevair in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Winrevair
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.